Personalized cyclosporine dosing after stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This study uses your own health data to help doctors find the best dose of cyclosporine for you, a medicine that helps prevent graft-versus-host disease after a stem cell transplant. The goal is to make the treatment more effective and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 2 and 65 years old.
- You have had your first stem cell transplant and are currently in stable condition.
- You are taking cyclosporine (or will be) to help prevent graft-versus-host disease, either by itself or with other medicines.
- Your blood samples for medication levels must be taken at the correct times and you need to have all the necessary health information for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug combo (cyclophosphamide, sirolimus, and ruxolitinib) works better than another combo (cyclophosphamide, sirolimus, and mycophenolate mofetil) to prevent graft versus host disease in people getting a stem cell transplant for certain blood cancers.
This study tests whether a lower dose of a drug called cyclophosphamide, given after a stem cell transplant from a half-matched donor, is safe and works as well as the standard dose. It may help reduce side effects for people with blood cancers.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
This trial studies giving cyclophosphamide after a stem cell transplant when there is no matched sibling donor, but a well-matched unrelated donor is available. It aims to improve outcomes for people with blood cancers undergoing this transplant.
This early-phase study tests giving cyclophosphamide after a specific type of stem cell transplant (haploidentical) in people age 65 and older. It aims to improve transplant safety and outcomes by adjusting medicine given after the graft is placed.
This study looks at whether giving a medicine called cyclophosphamide after a stem cell transplant helps work better and for whom. You may be eligible if you are planning a certain type of transplant and your team plans to give post-transplant cyclophosphamide.
Hear when a new Bone Marrow Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.